Lyka Labs Ltd

₹ 126 -1.72%

25 Apr 4:05 p.m.

About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages^[1]

Key Points

Business Overview:^[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

Website BSE NSE

Market Cap ₹ 418 Cr.
Current Price ₹ 126
High / Low ₹ 144 / 88.5
Stock P/E
Book Value ₹ 20.6
Dividend Yield 0.00 %
ROCE 4.93 %
ROE -28.4 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Promoter holding has increased by 3.29% over last quarter.

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 9.25% over past five years.
Debtor days have increased from 50.1 to 79.0 days.
Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
	26.81	24.26	49.44	73.89	35.57	35.19	27.49	25.53	17.82	22.24	22.88	27.99	32.56
	20.80	18.02	19.54	28.27	22.55	22.59	21.18	20.50	15.61	18.94	20.24	23.82	25.69
Operating Profit	6.01	6.24	29.90	45.62	13.02	12.60	6.31	5.03	2.21	3.30	2.64	4.17	6.87
OPM %	22.42%	25.72%	60.48%	61.74%	36.60%	35.81%	22.95%	19.70%	12.40%	14.84%	11.54%	14.90%	21.10%
	0.70	-0.50	0.47	-3.20	0.58	-2.27	0.95	0.98	-5.95	0.02	0.38	-0.18	0.54
Interest	6.59	6.37	6.93	5.57	4.64	2.99	2.91	3.03	3.08	2.85	1.35	1.19	1.28
Depreciation	2.12	2.02	2.13	3.52	2.24	9.46	3.59	3.62	3.47	3.47	3.47	3.59	2.84
Profit before tax	-2.00	-2.65	21.31	33.33	6.72	-2.12	0.76	-0.64	-10.29	-3.00	-1.80	-0.79	3.29
Tax %	7.00%	159.25%	8.59%	16.98%	6.55%	-607.08%	6.58%	46.88%	-2.24%	0.00%	-7.22%	22.78%	38.60%
	-2.27	1.14	19.55	28.43	6.09	-15.07	0.60	-0.38	-10.42	-3.01	-1.85	-0.49	1.78
EPS in Rs	-0.79	0.40	6.81	9.91	2.12	-5.25	0.21	-0.13	-3.63	-0.98	-0.56	-0.15	0.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	170	127	119	166	130	110	60	71	61	86	194	93	106
	155	99	111	139	110	87	63	73	65	67	93	76	89
Operating Profit	15	28	8	28	20	23	-4	-2	-4	20	101	17	17
OPM %	9%	22%	7%	17%	16%	21%	-6%	-3%	-6%	23%	52%	18%	16%
	16	3	25	4	8	-2	4	1	-30	0	-4	-4	1
Interest	30	19	27	24	15	19	10	7	20	26	20	12	7
Depreciation	9	12	9	11	9	10	11	7	8	8	17	14	13
Profit before tax	-8	0	-3	-3	4	-8	-20	-15	-62	-14	59	-13	-2
Tax %	0%	0%	-45%	-31%	-5%	19%	5%	59%	-1%	29%	35%	0%
	-8	-1	-5	-5	4	-7	-19	-6	-63	-10	38	-13	-4
EPS in Rs	-3.20	-0.33	-3.05	-2.29	1.67	-2.51	-6.14	-1.97	-21.10	-4.03	13.59	-4.30	-1.15
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-3%
5 Years:	9%
3 Years:	15%
TTM:	0%

Compounded Profit Growth
10 Years:	%
5 Years:	11%
3 Years:	22%
TTM:	90%

Stock Price CAGR
10 Years:	26%
5 Years:	34%
3 Years:	55%
1 Year:	21%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	-28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	22	22	22	22	22	22	28	28	29	29	29	31	33
Reserves	51	44	30	20	22	16	21	14	-43	-54	-15	-3	35
Preference Capital	1	1	1	1	1	0	1	1	1	1	1	1
	133	126	163	136	120	126	112	96	141	163	130	74	54
	77	97	114	102	78	88	69	78	74	53	43	50	30
Total Liabilities	283	289	329	279	242	252	229	216	200	190	186	152	152
	137	93	162	122	104	133	116	108	105	98	94	68	63
CWIP	8	47	22	27	30	24	28	31	28	26	18	16	17
Investments	6	6	0	0	0	0	0	0	0	0	0	0	0
	132	143	145	130	107	94	85	77	68	66	74	67	71
Total Assets	283	289	329	279	242	252	229	216	200	190	186	152	152

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	1	11	89	27	12	31	11	27	5	9	79	9
	12	5	-57	37	17	-13	-3	-4	-0	-0	-6	7
	-16	-13	-26	-60	-30	-19	-10	-23	3	-12	-63	-22
Net Cash Flow	-3	3	6	4	-1	-0	-3	-1	9	-3	10	-5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	131	211	209	124	121	97	125	75	48	37	35	79
Inventory Days	57	99	91	77	56	90	139	65	69	41	56	68
Days Payable	158	236	363	220	218	266	301	216	192	141	96	91
Cash Conversion Cycle	30	73	-64	-18	-41	-79	-37	-75	-76	-63	-5	55
Working Capital Days	63	96	-106	-88	-75	-191	-456	-181	-156	-71	6	34
ROCE %	5%	10%	2%	10%	7%	9%	-8%	-5%	-6%	10%	61%	5%

Shareholding Pattern

Numbers in percentages

1 Recently

	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Apr 2024
	20.00%	20.04%	47.79%	47.80%	47.58%	47.58%	51.00%	54.58%	54.81%	54.81%	54.81%	58.11%
	2.07%	1.13%	1.12%	0.76%	0.57%	0.37%	0.18%	0.17%	0.18%	0.17%	0.17%	0.16%
	1.85%	0.47%	1.19%	3.99%	4.00%	4.00%	3.74%	0.41%	0.41%	0.62%	0.81%	0.75%
	76.08%	78.36%	49.89%	47.45%	47.85%	48.05%	45.08%	44.84%	44.61%	44.41%	44.21%	40.98%
No. of Shareholders	20,672	27,720	26,220	26,969	28,433	28,515	26,820	27,202	26,652	26,422	25,717	25,699

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Apr 2024
	23.99%	18.66%	18.13%	19.88%	19.88%	47.79%	51.00%	54.81%	58.11%
	4.74%	3.57%	3.64%	3.50%	3.50%	1.12%	0.18%	0.17%	0.16%
	1.70%	1.01%	1.01%	0.66%	0.47%	1.19%	3.74%	0.81%	0.75%
	69.57%	76.75%	77.22%	75.96%	76.15%	49.89%	45.08%	44.21%	40.98%
No. of Shareholders	19,769	20,791	20,281	19,642	19,350	26,220	26,820	25,717	25,699

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Lyka Labs Ltd

Lyka Labs Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings